These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28272733)

  • 21. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Sallee FR; Lyne A; Wigal T; McGough JJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
    Alamo C; López-Muñoz F; Sánchez-García J
    Actas Esp Psiquiatr; 2016 May; 44(3):107-12. PubMed ID: 27254403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.
    Sayer GR; McGough JJ; Levitt J; Cowen J; Sturm A; Castelo E; McCracken JT
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):882-888. PubMed ID: 27483130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Stimulant and non-stimulant medication in current and future therapy for ADHD].
    Franke AG; Konrad A; Lieb K; Huss M
    Fortschr Neurol Psychiatr; 2012 Mar; 80(3):130-40. PubMed ID: 21611939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.
    Butterfield ME; Saal J; Young B; Young JL
    Psychiatry Res; 2016 Feb; 236():136-141. PubMed ID: 26730446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F; Connor DF; Newcorn JH
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
    Mattes JA
    J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
    Capone GT; Brecher L; Bay M
    J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
    Buoli M; Serati M; Cahn W
    Expert Rev Neurother; 2016; 16(2):131-44. PubMed ID: 26693882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Connor DF; Arnsten AF; Pearson GS; Greco GF
    Expert Opin Pharmacother; 2014 Aug; 15(11):1601-10. PubMed ID: 24992513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of extended-release drug formulations for the treatment of ADHD.
    Childress A
    Expert Opin Drug Saf; 2017 May; 16(5):603-615. PubMed ID: 28393639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
    Sallee FR; Eaton K
    Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.